US Stock market today saw the Dow, S&P 500, and Nasdaq inch higher as Wall Street kicked off a packed week of Big Tech ...

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient ...

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...

The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements. | The FDA is shutting ...

In June 2025, the US Food and Drug Administration (FDA) announced a major update to its General Food Labeling Requirements Compliance Program—the first overhaul of this program since 2010. This ...

Today's biotech news features an FDA probe into the deaths tied to Sarepta's Duchenne drug, rejecting KalVista's drug application, etc.

Sabores Fit Bakery recalled a variety of its mousse desserts on June 20 because of the undeclared presence of allergens.

Supermarket chain Hy-Vee issued a voluntary recall for a range of sushi products on June 5 for possible listeria contamination.

A popular dessert sold in Florida is now under a Class I recall after the FDA discovered a dangerous labeling issue involving hidden allergens.

Alma Pak International has issued a voluntary recall of bulk organic blueberries, affecting 400 boxes, each containing 30 pounds of the fruit.

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene therapy ...

Olympus shares fell sharply after the U.S. Food and Drug Administration issued alerts to stop imports of certain medical devices made by the company in Japan. Shares closed 11% lower at 1,691.5 ...